Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 1/20 | 0.48 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.48 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.48 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14029873 | 0.88 | HPGD (0.48) | SMN1; SMN2ALDH1A1GAAMAPTLMNA | |
| SCHEMBL14029827 | 0.84 | CACNA1B (0.43) | CACNA1BAPBA1SAE1UBA2SMN1; SMN2 | |
| SCHEMBL20509703 | 0.80 | SMN1; SMN2 (0.56) | CACNA1BAPBA1SAE1UBA2SMN1; SMN2 | |
| SCHEMBL30779603 | 0.80 | SMN1; SMN2 (0.56) | CACNA1BAPBA1SAE1UBA2SMN1; SMN2 | |
| SCHEMBL5002691 | 0.80 | MAPK1 (0.51) | CACNA1BAPBA1SAE1UBA2SMN1; SMN2 | |
| SCHEMBL14924966 | 0.80 | RAB9A (0.51) | CACNA1BAPBA1SAE1UBA2SMN1; SMN2 | |
| SCHEMBL5002661 | 0.77 | KMT2A (0.47) | SMN1; SMN2ALDH1A1GAAMAPTLMNA | |
| SCHEMBL14029795 | 0.77 | MAPK1 (0.47) | SMN1; SMN2ALDH1A1MAPK1MAPTLMNA | |
| SCHEMBL14029825 | 0.76 | CACNA1B (0.49) | CACNA1BAPBA1SAE1UBA2SMN1; SMN2 | |
| SCHEMBL14924997 | 0.75 | HPGD (0.46) | SMN1; SMN2ALDH1A1MAPTLMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130116251-A1 | Novel HSP90 Inhibitor | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2013-05-09 | — | — | US | disclosed |
| US-20130116252-A1 | Novel HSP90 Inhibitor | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2013-05-09 | — | — | US | disclosed |
| US-20130116431-A1 | Novel HSP90 Inhibitor | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2013-05-09 | — | — | US | disclosed |
| US-20130116253-A1 | Novel HSP90 Inhibitor | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2013-05-09 | — | — | US | disclosed |
| EP-1857446-B1 | Derivatives of 3-(2,4-dihydroxyphenyl)-1,2,4-triazole useful in the treatment of cancer | NIPPON KAYAKU KK (JP) | 2013-05-01 | — | — | EP | disclosed |
| US-8399464-B2 | using a triazole compound; anticancer agent | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2013-03-19 | — | — | US | disclosed |
| US-8399464-B2 | using a triazole compound; anticancer agent | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2013-03-19 | — | — | US | disclosed |
| US-20080269218-A1 | Novel Hsp90 Inhibitor | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2008-10-30 | — | — | US | disclosed |
| US-20080269218-A1 | Novel Hsp90 Inhibitor | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2008-10-30 | — | — | US | disclosed |
| EP-1857446-A1 | NOVEL HSP90 INHIBITOR | Nippon Kayaku Kabushiki Kaisha (JP) | 2007-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116252-A1 | Novel HSP90 Inhibitor | HSP90AB1, HSP90AB2P, HSP90B1 | CACNA1B 4791/4885APBA1 3549/4885SAE1 474/4885 |
| US-20130116253-A1 | Novel HSP90 Inhibitor | HSP90AB1, HSP90AB2P, HSP90B1 | CACNA1B 4791/4885APBA1 3549/4885SAE1 474/4885 |
| US-20080269218-A1 | Novel Hsp90 Inhibitor | HSP90AB1, HSP90AB2P, HSP90B1 | CACNA1B 4826/4885APBA1 3702/4885SAE1 592/4885 |
| US-20130116251-A1 | Novel HSP90 Inhibitor | HSP90AB1, HSP90AB2P, HSP90B1 | CACNA1B 4791/4885APBA1 3549/4885SAE1 474/4885 |
| US-20130116431-A1 | Novel HSP90 Inhibitor | HSP90AB1, HSP90AB2P, HSP90B1 | CACNA1B 4791/4885APBA1 3549/4885SAE1 474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.